Redcliffe Lifetech has 6 close competitors: BioLinq, Calyxo, Egenesis.
Sector, valuation and status for each competitor.
competitor›
competitor›
competitor›
competitor›A private valuation and a public market cap share one column; each row names its basis and date.
BioLinqCalyxoEgenesisAbridgeIndian diagnostic lab and healthcare technology company
Redcliffe Lifetech competes with 6 companies here: BioLinq, Calyxo, Egenesis, Kriya Therapeutics, Abridge, Alloy Therapeutics.
Redcliffe Lifetech was last valued at $150M . That price was agreed in one transaction and holds until the next round. A listed competitor is repriced every trading session.
The closest healthcare peers are on the competitors page.
The routes section explains what is realistically available for a company at this stage.
No. Redcliffe Lifetech is a private company; its shares do not trade on a public exchange.
The last valuation is $150M.
Perpetual markets for stocks, gold, indices and pre-IPO names — settled on-chain, no wallet-to-exchange transfers.
